Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Change in Account Payables (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Change in Account Payables data on record, last reported at -$2.0 million in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 157.61% year-over-year to -$2.0 million; the TTM value through Sep 2025 reached -$5.7 million, down 160.79%, while the annual FY2024 figure was $11.7 million, 2908.61% up from the prior year.
  • Change in Account Payables reached -$2.0 million in Q3 2025 per ZBIO's latest filing, up from -$12.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.4 million in Q4 2024 and bottomed at -$12.1 million in Q2 2025.
  • Average Change in Account Payables over 3 years is $462625.0, with a median of $3.0 million recorded in 2023.
  • Peak YoY movement for Change in Account Payables: skyrocketed 73.75% in 2024, then plummeted 2418.12% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $3.1 million in 2023, then surged by 73.75% to $5.4 million in 2024, then tumbled by 136.05% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$2.0 million in Q3 2025, -$12.1 million in Q2 2025, and $2.9 million in Q1 2025.